Failure of SKF 38393‐A to relieve parkinsonian symptoms induced by 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine in the marmoset

Open Access
Publisher Website
Google Scholar
Abstract
Chronic administration of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) induced parkinsonian symptoms, predominantly bradykinesia and tremor, in marmosets. These symptoms were reduced by L‐DOPA plus benserazide but the putative D1‐preceptor agonist SKF 38393‐A did not affect tremor and increased the bradykinesia. Neither treatment affected behaviour in normal marmosets. It is suggested that D1‐receptor agonists are unlikely to be effective in the treatment of Parkinson's disease.